Pharming Group (NASDAQ:PHAR) Shares Gap Down to $8.12

Pharming Group (NASDAQ:PHAR) shares gapped down before the market opened on Wednesday . The stock had previously closed at $8.12, but opened at $7.86. Pharming Group shares last traded at $7.86, with a volume of 161 shares changing hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Thursday, August 1st.

Pharming Group Price Performance

The stock has a market capitalization of $502.39 million, a PE ratio of -50.75 and a beta of 0.15. The business’s 50-day moving average price is $8.11 and its 200 day moving average price is $9.46. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. The business had revenue of $74.09 million for the quarter, compared to analysts’ expectations of $71.95 million. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. During the same quarter in the previous year, the firm earned $0.02 earnings per share. Research analysts forecast that Pharming Group will post -0.03 earnings per share for the current year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,435 shares of the company’s stock after buying an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.